Aciclovir Dispersible Tablets 200mg
Aciclovir Dispersible Tablets 200 mg
Each tablet contains Aciclovir BP 200 mg
Dispersible film-coated tablet
Aciclovir Dispersible Tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes; for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immunocompetent patients; for the prophylaxis of herpes simplex infections in immunocompromised patients and for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections.
Treatment of herpes simplex infections: 200 mg Aciclovir should be taken five times daily at approximately four hourly intervals omitting the night time dose. Treatment should continue for 5 days, but in severe initial infections this may have to be extended.
In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut the dose can be doubled to 400 mg Aciclovir or alternatively intravenous dosing could be considered.
Dosing should begin as early as possible after the start of an infection; for recurrent episodes this should preferably be during the prodromal period or when lesions first appear.
Suppression of herpes simplex infections in immunocompetent patients: 200 mg Aciclovir should be taken four times daily at approximately six-hourly intervals.
Many patients may be conveniently managed on a regimen of 400 mg Aciclovir twice daily at approximately twelve-hourly intervals.
Dosage titration down to 200 mg Aciclovir taken thrice daily at approximately eight-hourly intervals or even twice daily at approximately twelve-hourly intervals, may prove effective.
Some patients may experience break-through infections on total daily doses of 800 mg Aciclovir.
Therapy should be interrupted periodically at intervals of six to twelve months, in order to observe possible changes in the natural history of the disease.
Prophylaxis of herpes simplex infections in immunocompromised patients:
Aciclovir should be taken four times daily at approximately six hourly intervals.
In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut, the dose can be doubled to 400 mg Aciclovir or, alternatively, intravenous dosing could be considered.
The duration of prophylactic administration is determined by the duration of the period at risk.
Treatment of varicella and herpes zoster infections: 800 mg Aciclovir should be taken five times daily at approximately four-hourly intervals, omitting the night time dose. Treatment should continue for seven days.
In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut, consideration should be given to intravenous dosing.
Dosing should begin as early as possible after the start of an infection: treatment of herpes zoster yields better results if initiated as soon as possible after the onset of the rash. Treatment of chickenpox in immunocompetent patients should begin within 24 hours after onset of the rash.
Treatment of herpes simplex infections, and prophylaxis of herpes simplex infections in the immunocompromised: Children aged two years and over should be given adult dosages and children below the age of two years should be given half the adult dose.
Treatment of varicella infections:
6 years and over: 800 mg Aciclovir four times daily.
2 to 5 years: 400 mg Aciclovir four times daily.
Under 2 years: 200 mg Aciclovir four times daily
Treatment should continue for five days. Dosing may be more accurately calculated as 20mg/kg body weight (not to exceed 800mg) aciclovir four times daily.
No specific data are available on the suppression of herpes simplex infections or the
treatment of herpes zoster infections in immunocompetent children.
The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly (see Dosage in renal impairment below).
Total aciclovir body clearance declines along with creatinine clearance.Adequate hydration of elderly patients taking high oral doses of aciclovir should be maintained.
Caution is advised when administering aciclovir to patients with impaired renal function.
Adequate hydration should be maintained.
In the management of herpes simplex infections in patients with severe renal impairment (creatinine clearance less than 10 ml/minute) an adjustment of dosage to 200 mg aciclovir twice daily at approximately twelve-hourly intervals is recommended.
In the management of herpes simplex infections in patients with impaired renal function, the recommended oral doses will not lead to accumulation of aciclovir above levels that have been established by intravenous infusion.
In the treatment of varicella and herpes zoster infections it is recommended to adjust the dosage to 800 mg aciclovir twice daily at approximately twelve-hourly intervals for patients with severe renal impairment (creatinine clearance less than 10 ml/minute), and to 800 mg aciclovir three times daily at intervals of approximately eight hours for patients with moderate renal impairment (creatinine clearance in the range 10 to 25 ml/minute).
Aciclovir dispersible tablets may be dispersed in a minimum of 50 ml of water or swallowed whole with a little water.
Aciclovir Tablets are contra-indicated in patients known to be hypersensitive to aciclovir and valaciclovir or to any of the excipients..
Adequate hydration should be maintained in high oral doses of aciclovir.
The risk of renal impairment is increased by use with other nephrotoxic drugs.
Use in patients with renal impairment and in elderly patients:
Aciclovir is eliminated by renal clearance, therefore the dose must be reduced in patients with renal impairment (see section 4.2). Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see section 4.8).
Prolonged or repeated courses of aciclovir in severely immune-compromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir treatment (see section 5.1).
The data currently available from clinical studies is not sufficient to conclude that treatment with aciclovir reduces the incidence of chickenpox - associated complications in immunocompetent patients.
The results of a wide range of mutagenicity tests in vitro and in vivo indicate that aciclovir is unlikely to pose a genetic risk to man. Aciclovir was not found to be carcinogenic in long term studies in the rat and the mouse. Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of aciclovir greatly in excess of those employed therapeutically. Aciclovir Tablets have been shown to have no definite effect upon sperm count, morphology or motility in man.
Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered concurrently that compete with this mechanism may increase aciclovir plasma concentrations. Probenecid and cimetidine increase the AUC of aciclovir by this mechanism, and reduce aciclovir renal clearance. Similarly increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients have been shown when the drugs are coadministered. However no dosage adjustment is necessary because of the wide therapeutic index of aciclovir.
An experimental study on five male subjects indicates that concomitant therapy with aciclovir increases AUC of totally administered theophylline with approximately 50%. It is recommended to measure plasma concentrations during concomitant therapy with aciclovir.
Probenecid increases the aciclovir mean half-life and area under the plasma concentrationtime curve. Other drugs affecting renal physiology could potentially influence the pharmacokinetics of aciclovir. However clinical experience has not identified other drug interactions with aciclovir.
There is no experience of the effects of Aciclovir Tablets on human female fertility.
Two-generation studies in mice did not reveal any effect of aciclovir on fertility.
Experience in humans is limited so the use of Aciclovir Tablets should be considered only when the potential benefits outweigh the possibility of unknown risks.
A post-marketing aciclovir pregnancy registry has documented pregnancy outcomes in women exposed to any formulation of aciclovir. The registry findings have not shown an increase in the number of birth defects amongst aciclovir exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause.Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rats, rabbits or mice.
In a non-standard test in rats, foetal abnormalities were observed, but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain.
Following oral administration of 200 mg aciclovir five times a day, aciclovir has been detected in breast milk at concentrations ranging from 0.6 to 4.1 times the corresponding plasma levels. These levels would potentially expose nursing infants to aciclovir dosages of up to 0.3 mg/kg/day. Caution is therefore advised if aciclovir is to be administered to a nursing woman.
The clinical status of the patient and the adverse event profile of aciclovir should be borne in mind when considering the patients’s ability to drive or operate machinery.
There have been no studies to investigate the effect of aciclovir on driving performance or the ability to operate machinery. Furthermore, a detrimental effect on such activities cannot be predicted from the pharmacology of the active substance.
The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.
The following convention has been used for the classification of undesirable effects in terms of frequency:- Very common >1/10, common >1/100 and <1/10, uncommon >1/1000 and <1/100, rare >1/10,000 and <1/1000, very rare <1/10,000.
Blood and lymphatic system disorders
Very rare: Anaemia, leukopenia, thrombocytopenia
Immune system disorders
Psychiatric and nervous system disorders
Common: Headache, dizziness, confusional states
Very rare: Agitation, confusion, tremor, ataxia, dysarthria, hallucinations,
psychoticsymptoms, convulsions, somnolence, encephalopathy, coma
The above events are generally reversible and usually reported in patients with renal impairment, or with other predisposing factors (see section 4.4).
Respiratory, thoracic and mediastinal disorders
Common: Nausea, vomiting, diarrhoea, abdominal pains
In double-blind, placebocontrolled trials the incidence of gastrointestinal events has not been found to differ between placebo and aciclovir recipients.
Rare: Reversible rises in bilirubin and liver related enzymes
V ery rare: Hepatitis, jaundice
Skin and subcutaneous tissue disorders
Common: Pruritus, rashes (including photosensitivity)
Uncommon: Urticaria, accelerated diffuse hair loss.
Accelerated diffuse hair loss has been associated with a wide variety of disease processes and medicines, the relationship of the event to aciclovir therapy is uncertain.
Renal and urinary disorders
Rare: Increases in blood urea and creatinine
Very rare: Acute renal failure, renal pain
Renal pain may be associated with renal failure.
General disorders and administration site conditions
Common: Fatigue, fever
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Symptoms and Signs
Aciclovir is only partly absorbed in the gastrointestinal tract.
Patients have ingested overdoses of up to 20g aciclovir on a single occasion, usually without toxic effects. Accidental, repeated overdoses of oral aciclovir over several days have been associated with gastrointestinal effects (such as nausea and vomiting) and neurological effects (headache and confusion).
Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with overdosage.
No data are available on the consequences of the ingestion of higher doses; such an occurrence warrants close observation of the patient.
Single intravenous doses of up to 80 mg/kg have been inadvertently administered without adverse effects. Aciclovir is dialysable by haemodialysis.
Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the blood and may, therefore, be considered a management option in the event of symptomatic overdose.
Aciclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against human herpes viruses, including herpes simplex virus (HSV) types I and II and varicella zoster virus (VZV).
The inhibitory activity of aciclovir for HSV I, HSV II and VZV is highly selective. The enzyme thymidine kinase (TK) of normal, uninfected cells does not use aciclovir effectively as a substrate, hence toxicity to mammalian host cells is low; however TK encoded by HSV and VZV converts aciclovir to aciclovir monophosphate, a nucleoside analogue which is further converted to the diphosphate and finally to the triphosphate by cellular enzymes. Aciclovir triphosphate interferes with the viral DNA polymerase and inhibits viral DNA replication with resultant chain termination following its incorporation into the viral DNA.
Prolonged or repeated courses of aciclovir in severely immunocompromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir treatment. Most of the clinical isolates with reduced sensitivity have been relatively deficient in viral TK, however, strains with altered viral TK or viral DNA polymerase have also been reported. In vitro exposure of HSV isolates to aciclovir can also lead to the emergence of less sensitive strains. The relationship between the in vitro determined sensitivity of HSV isolates and clinical response to aciclovir therapy is not clear.
Aciclovir is only partially absorbed from the gut. Mean steady state peak plasma concentrations (CssMax) following doses of 200 mg aciclovir administered four hourly were 3.1 microMol (0.7 micrograms/ml) and the equivalent trough plasma levels (CssMin) were 1.8 microMol (0.4 micrograms/ml). Corresponding steady state plasma concentrations following doses of 400 mg and 800 mg aciclovir administered four-hourly were 5.3 microMol (1.2 micrograms/ml) and 8 microMol (1.8 micrograms/ml) respectively, and equivalent trough plasma levels were 2.7 microMol (0.6 micrograms/ml) and 4 microMol (0.9 micrograms/ml).
In adults the terminal plasma half life after administration of intravenous aciclovir is about 2.9 hours. Most of the drug is excreted unchanged by the kidney. Renal clearance of aciclovir is substantially greater than creatinine clearance, indicating that tubular secretion, in addition to glomerular filtration, contributes to the renal elimination of the drug. 9-carboxymethoxy-methylguanine is the only significant metabolite of aciclovir, and accounts for 10 to 15% of the dose excreted in the urine. When aciclovir is given one hour after 1 gram of probenecid the terminal half life and the area under the plasma concentration time curve is extended by 18% and 40% respectively.
In adults, mean steady state peak plasma concentrations (CssMax) following a one hour infusion of 2.5 mg/kg, 5 mg/kg and 10 mg/kg were 22.7 microMol (5.1 micrograms/ml), 43.6 microMol (9.8 micrograms/ml) and 92 microMol (20.7 micrograms/ml), respectively. The corresponding trough levels (Cssmin) 7 hours later were 2.2 microMol (0.5 micrograms/ml), 3.1 microMol (0.7 micrograms/ml) and 10.2 microMol (2.3 micrograms/ml), respectively.
In children over 1 year of age similar mean peak (CssMax) and trough (CssMin) levels were observed when a dose of 250 mg/m2 was substituted for 5 mg/kg and a dose of 500 mg/m2
was substituted for 10 mg/kg. In neonates (0 to 3 months of age) treated with doses of 10 mg/kg administered by infusion over a one hour period every 8 hours the CssMax was found to be 61.2 microMol (13.8 micrograms/ml) and CssMin to be 10.1 microMol (2.3 micrograms/ml). The terminal plasma half life in these patients was 3.8 hours.
In the elderly total body clearance falls with increasing age associated with decreases in creatinine clearance although there is little change in the terminal plasma half life.
In patients with chronic renal failure the mean terminal half life was found to be 19.5 hours. The mean aciclovir half life during haemodialysis was 5.7 hours. Plasma aciclovir levels dropped approximately 60% during dialysis.
Cerebrospinal fluid levels are approximately 50% of corresponding plasma levels. Plasma protein binding is relatively low (9 to 33%) and drug interactions involving binding site displacement are not anticipated.
No additional information is presented.
Microcrystalline Cellulose EP Aluminium Magnesium Silicate BP Sodium Starch Glycollate BP Povidone K30 EP Magnesium Stearate EP Indigo Carmine E132 HSE
Industrial Methylated Spirit BP or Ethanol (96%) BP Purified Water EP
Coating concentrate OY-7240 clear containing: Hypromellose EP Polyethylene Glycol 400 USNF Purified Water EP
Polyethylene Glycol 8000 USNF Purified Water EP
36 months shelf life in the product as packaged
Store below 30°C, keep dry, protect from light.
PVdC coated uPVC/aluminium foil blister packs (min. 40 gm-2 PVdC on 250 pm uPVC/20 pm Al) of 25 tablets.
Norton Healthcare Limited Ridings Point,